Viking Therapeutics ROE - Return on Equity 2014-2024 | VKTX

Viking Therapeutics return on equity for the quarter ending September 30, 2024 was -12.72.

  • Viking Therapeutics average return on equity for 2023 was -36.44, a 7.59% decline from 2022.
  • Viking Therapeutics average return on equity for 2022 was -33.87, a 57.98% increase from 2021.
  • Viking Therapeutics average return on equity for 2021 was -21.44, a 63.79% increase from 2020.

Roe - return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.

Viking Therapeutics ROE - Return on Equity 2014-2024 | VKTX

  • Viking Therapeutics average return on equity for 2023 was -36.44, a 7.59% decline from 2022.
  • Viking Therapeutics average return on equity for 2022 was -33.87, a 57.98% increase from 2021.
  • Viking Therapeutics average return on equity for 2021 was -21.44, a 63.79% increase from 2020.

Roe - return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.